Results of the ENDEAVOR trial comparing carfilzomib and bortezomib in multiple myeloma

Dr Joseph Mikhael discusses the results of the ENDEAVOR trial, a phase 3 head-to-head study that demonstrates superiority of carfilzomib over bortezomib in patients with relapsed multiple myeloma.

Share this video  
2nd June 2015